



## **Bolt Biotherapeutics to Participate in Upcoming March Conferences**

February 24, 2026

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March:

- **TD Cowen 46th Annual Health Care Conference**  
Company presentation on Monday, March 2, 2026 at 9:50 a.m. EST (6:50 a.m. PST)
- **Leerink Partners Global Healthcare Conference**  
Participating in 1x1 meetings on Wednesday, March 11, 2026

### **About Bolt Biotherapeutics, Inc.**

The mission of Bolt Biotherapeutics is to harness the power of the immune system to improve lives and eradicate cancer. The Company is developing BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-4182 is currently in a Phase 1 dose escalation trial that includes patients with gastric and gastroesophageal cancer. The Company has strategic collaborations with Genmab and Toray built around the Company's Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform technology and its expertise in myeloid biology. The Company is seeking to partner BDC-3042, a Dectin-2 agonist that recently completed a first-in-human Phase 1 dose escalation trial, as well as its preclinical ISAC programs targeting CEA and PD-L1.

For more information, please visit <https://www.boltbio.com/>.

### **Investor Relations and Media Contact:**

Matthew DeYoung  
Argot Partners  
(212) 600-1902  
[boltbio@argotpartners.com](mailto:boltbio@argotpartners.com)